JP2020518276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518276A5 JP2020518276A5 JP2019561141A JP2019561141A JP2020518276A5 JP 2020518276 A5 JP2020518276 A5 JP 2020518276A5 JP 2019561141 A JP2019561141 A JP 2019561141A JP 2019561141 A JP2019561141 A JP 2019561141A JP 2020518276 A5 JP2020518276 A5 JP 2020518276A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- human
- nuclease
- nucleic acid
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022175346A JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503060P | 2017-05-08 | 2017-05-08 | |
| US62/503,060 | 2017-05-08 | ||
| US201762579460P | 2017-10-31 | 2017-10-31 | |
| US62/579,460 | 2017-10-31 | ||
| PCT/US2018/031674 WO2018208837A1 (en) | 2017-05-08 | 2018-05-08 | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022175346A Division JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518276A JP2020518276A (ja) | 2020-06-25 |
| JP2020518276A5 true JP2020518276A5 (enExample) | 2021-06-10 |
| JP7170666B2 JP7170666B2 (ja) | 2022-11-14 |
Family
ID=62555183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561141A Expired - Fee Related JP7170666B2 (ja) | 2017-05-08 | 2018-05-08 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| JP2022175346A Pending JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022175346A Pending JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10745665B2 (enExample) |
| EP (2) | EP3634493A1 (enExample) |
| JP (2) | JP7170666B2 (enExample) |
| AU (1) | AU2018266698A1 (enExample) |
| CA (1) | CA3062698A1 (enExample) |
| WO (1) | WO2018208837A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200190541A1 (en) * | 2017-04-28 | 2020-06-18 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| CN112585276A (zh) * | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| EP3887395A4 (en) * | 2018-11-30 | 2022-07-27 | Intima Bioscience, Inc. | METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES |
| EP4332115A3 (en) | 2019-04-03 | 2024-05-29 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| WO2020254528A1 (en) * | 2019-06-18 | 2020-12-24 | Celyad Oncology S.A. | Cd52-deficient cells for adoptive cell therapy |
| WO2021062267A1 (en) * | 2019-09-26 | 2021-04-01 | Nantbio, Inc. | Primary t-cell expansion |
| JP7821119B2 (ja) * | 2020-04-23 | 2026-02-26 | エーゼットセラピーズ， インコーポレイテッド | Ｈｌａクラスｉ ｍｈｃの細胞切除 |
| GB202006587D0 (en) * | 2020-05-04 | 2020-06-17 | Celyad S A | Improved scaffolds for multiplexed inhibitory rna |
| AU2021372458A1 (en) * | 2020-10-26 | 2023-06-15 | Research Institute At Nationwide Children's Hospital | Chimeric antigen receptor (car) nk cells and uses thereof |
| MX2023006878A (es) | 2020-12-11 | 2023-07-31 | Intellia Therapeutics Inc | Composiciones y métodos para reducir el mhc de clase ii en una célula. |
| WO2022140586A2 (en) | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions and methods for reducing hla-a in a cell |
| EP4267723A1 (en) | 2020-12-23 | 2023-11-01 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying ciita in a cell |
| JP2024502036A (ja) | 2020-12-30 | 2024-01-17 | インテリア セラピューティクス，インコーポレイテッド | 操作されたｔ細胞 |
| WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| WO2022170193A2 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy |
| EP4288088A2 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy |
| JP2024505672A (ja) | 2021-02-08 | 2024-02-07 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のためのナチュラルキラー細胞受容体２ｂ４組成物及び方法 |
| AU2022301099A1 (en) * | 2021-07-01 | 2024-02-15 | Ningbo T-Maximum Biopharmaceuticals Co., Ltd. | Antigen-binding polypeptide targeting b7h3 and application thereof |
| JP2024534114A (ja) | 2021-08-24 | 2024-09-18 | インテリア セラピューティクス，インコーポレイテッド | 細胞療法用のプログラム細胞死タンパク質１（ｐｄ１）組成物及び方法 |
| WO2023081200A2 (en) | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
| EP4540389A2 (en) | 2022-06-16 | 2025-04-23 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
| WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
| TW202503051A (zh) | 2023-03-07 | 2025-01-16 | 美商英特利亞醫療公司 | 用於免疫療法之ｃｉｓｈ組合物及方法 |
| WO2025038648A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| IL330230A (en) | 2023-12-20 | 2026-08-01 | Intellia Therapeutics Inc | Engineered T cells |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| JP4012243B2 (ja) | 1994-01-18 | 2007-11-21 | ザ スクリップス リサーチ インスティチュート | 亜鉛フィンガータンパク質誘導体およびそのための方法 |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| CA2196419C (en) | 1994-08-20 | 2007-08-21 | Yen Choo | Improvements in or relating to binding proteins for recognition of dna |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| ATE347593T1 (de) | 2002-01-23 | 2006-12-15 | Univ Utah Res Found | Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US9447434B2 (en) | 2002-09-05 | 2016-09-20 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| ES2422291T3 (es) | 2007-10-31 | 2013-09-10 | Prec Biosciences Inc | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| US20140115726A1 (en) | 2011-04-05 | 2014-04-24 | Cellectis | New tale-protein scaffolds and uses thereof |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| RU2752933C2 (ru) * | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| KR102546296B1 (ko) * | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| BR112017020750A2 (en) * | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
| MX2017015239A (es) * | 2015-05-29 | 2018-02-19 | Juno Therapeutics Inc | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| ES2803728T3 (es) * | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| US20190017075A1 (en) * | 2015-12-23 | 2019-01-17 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| US20190241910A1 (en) * | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
-
2018
- 2018-05-08 JP JP2019561141A patent/JP7170666B2/ja not_active Expired - Fee Related
- 2018-05-08 AU AU2018266698A patent/AU2018266698A1/en not_active Abandoned
- 2018-05-08 WO PCT/US2018/031674 patent/WO2018208837A1/en not_active Ceased
- 2018-05-08 EP EP18729846.8A patent/EP3634493A1/en not_active Withdrawn
- 2018-05-08 EP EP21209275.3A patent/EP4029943A1/en active Pending
- 2018-05-08 CA CA3062698A patent/CA3062698A1/en active Pending
-
2019
- 2019-11-08 US US16/678,600 patent/US10745665B2/en active Active
-
2020
- 2020-07-13 US US16/927,452 patent/US20200339952A1/en not_active Abandoned
-
2022
- 2022-04-04 US US17/712,864 patent/US20220228115A1/en active Pending
- 2022-11-01 JP JP2022175346A patent/JP2023022005A/ja active Pending